

Special Issue

Novel Therapeutic Approaches for Chronic Urticaria: Advances and Challenges

Message from the Guest Editor

Chronic urticaria (CU) is a prevalent and challenging condition characterized by recurring hives and/or angioedema, significantly affecting patients' quality of life. While progress in understanding CU has led to new therapies, many patients remain unresponsive to standard treatments, underscoring the need for novel approaches. Recent advances include the development of biologics targeting specific immune pathways, such as anti-IgE and anti-cytokine therapies, which have shown promise in improving treatment outcomes. Additionally, new small molecules and innovative formulations are being explored to enhance efficacy and safety. Personalized medicine, focusing on biomarkers and genetic profiles, is also emerging as a potential game-changer in tailoring treatments to individual patients. This Special Issue invites original research and review articles on the latest therapeutic advancements in CU, including novel biologics, small molecules, personalized treatment strategies, and drug repurposing. Our goal is to highlight cutting-edge developments and explore future directions that will improve CU management and enhance patient care.

Guest Editor

Dr. Luis Felipe Ensina

Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo 01308-000, Brazil

Deadline for manuscript submissions

closed (28 July 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/217828

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)